The MHRA has approved inavolisib for adults with PIK3CA-mutated HR+/HER2– breast cancer, offering a new targeted first-line therapy that significantly prolongs progression-free survival.
Medscape News UK
Source link : https://www.medscape.com/viewarticle/mhra-approves-inavolisib-pik3ca-mutated-breast-cancer-2025a1000x72?src=rss
Author :
Publish date : 2025-11-27 13:09:00
Copyright for syndicated content belongs to the linked Source.